Dr. med. Dominik Mestel

1999-2006
Studium der Humanmedizin an der Ludwig-Maximilians-Universität München, Deutschland

2005
Gaststudium und Praktisches Jahr an der University of Cape Town (“Chris-Barnard-Division of Cardiothoracic Surgery”) Südafrika

2006
Staatsexamen

2008
Promotion zum Dr. med.

2012
Facharzttitel Dermatologie und Venerologie
Zusatzbezeichnung Medikamentöse Tumortherapie (D)

2016
Zusatzbezeichnung Proktologie (D)

2006-2010
Assistenzarzt für Dermatologie, Dermatologische Klinik – Charité-Universitätsmedizin Berlin (Chefarzt Prof. Dr. med. W. Sterry)

2010-2011
Assistenzarzt für Dermatologie, Dermatochirurgische Praxis, Berlin (Inhaber Dr. med. P. Uhl – Facharzt für Chirurgie und Facharzt für Dermatologie)

2011-2012
Assistenzarzt für Proktologie, Praxis Dr. Rothhaar & Kollegen, Berlin

2011-2015
Facharzt, Praxis Dr. Rothhaar & Kollegen, Berlin

2015-2016
Leitung der Bereiche Proktologie und Kutane Lymphome, Dermatologische Klinik, Charité-Universitätsmedizin Berlin (Kommissarischer Chefarzt Prof. Dr. med. Dr. h.c. T. Zuberbier)

2015-2016
Leitender Arzt, Praxiszentrum Kleinmachnow, Charité-Partnerpraxis (Inhaber Prof. Dr. med. Dr. h.c. T. Zuberbier, Prof. Dr. med. M. Maurer, PD, Dr. med. M. Hofmann)

2017-2018
Oberarzt und Medizinischer Standortleiter Dermatologie Winterthur, Pallas-Kliniken AG

Deutsch, Englisch, Französisch

Deutsche Dermatologische Gesellschaft (DDG)
Foederatio Medicorum Helveticorum (FMH)
Aerztegesellschaft Winterthur-Andelfingen (AWA)

Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists. Haenssle HA, Fink C, Schneiderbauer R, Toberer F, Buhl T, Blum A, Kalloo A, Hassen ABH, Thomas L, Enk A, Uhlmann L; Reader study level-I and level-II Groups. Collaborators (55) Alt C, Arenbergerova M, Bakos R, Baltzer A, Bertlich I, Blum A, Bokor-Billmann T, Bowling J, Braghiroli N, Braun R, Buder-Bakhaya K, Buhl T, Cabo H, Cabrijan L, Cevic N, Classen A, Deltgen D, Fink C, Georgieva I, Hakim-Meibodi LE, Hanner S, Hartmann F, Hartmann J, Haus G, Hoxha E, Karls R, Koga H, Kreusch J, Lallas A, Majenka P, Marghoob A, Massone C, Mekokishvili L, Mestel D, Meyer V, Neuberger A, Nielsen K, Oliviero M, Pampena R, Paoli J, Pawlik E, Rao B, Rendon A, Russo T, Sadek A, Samhaber K, Schneiderbauer R, Schweizer A, Toberer F, Trennheuser L, Vlahova L, Wald A, Winkler J, Wölbing P, Zalaudek I. Ann Oncol. 2018 Aug 1;29(8):1836-1842

S2k guideline: HPV-associated lesions of the external genital region and the anus – anogenital warts and precancerous lesions of the vulva, the penis, and the peri- and intra-anal skin (short version). Gross GE, Werner RN, Becker JC, Brockmeyer NH, Esser S, Hampl M, Hommel S, Jongen J, Mestel DS, Meyer T, Petry KU, Plettenberg A, Püschel K, Schneede P, Schöfer H, Sotlar K, Weyandt G, Wieland U, Wiese-Posselt M, Nast A. J Dtsch Dermatol Ges. 2018 Feb;16(2):242-256

S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 2: Treatment and Follow-up (ICD10 C82 – C86). Dippel E, Assaf C, Becker JC, von Bergwelt M, Beyer, M, Cozzio A, Eich H, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Loquai C, Meiss, F, Mestel DS, Nashan D, Nicolay J, Oschlies I, Schlaak M, Stoll C, VagT, Weichenthal M, Wobser M, Stadler R. J Dtsch Dermatol Ges. 2018 Jan;16(1):112-122

S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 1: Classification and Diagnosis (ICD10 C82 – C86). Dippel E, Assaf C, Becker JC, von Bergwelt M, Beyer, M, Cozzio A, Eich H, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Loquai C, Meiss, F, Mestel DS, Nashan D, Nicolay J, Oschlies I, Schlaak M, Stoll C, VagT, Weichenthal M, Wobser M, Stadler R. J Dtsch Dermatol Ges. 2017 Dec;15(12):1266-1273

Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas. Terhorst D, Mestel DS, Humme D, Sterry W, Beyer M (2012). Brit J Dermatol. 166:1295-300

Nestin and SOX9 and SOX10 transcription factors are co-expressed in melanoma. Bakos R, Maier, T, Besch R, Mestel DS, Ruzicka T, Sturm R, Berking C (2009). Exp Dermatol, 19:89-94

Treatment of cutaneous lymphomas: today and tomorrow. Mestel DS, Beyer M, Steinhoff M, Sterry W (2009). Actas Dermosifiliogr, Suppl. 1:18-32

The treatment of mycosis fungoides. Mestel DS, Beyer M, Steinhoff M, Sterry W, Assaf C (2008) G. Ital Dermatol Venereol 143:395-408

Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome. Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C (2008). Expert Opin Biol Ther 8:1929-1939

Emerging drugs in cutaneous T-cell Lymphoma. Mestel DS, Assaf C, Steinhoff M, Beyer M, Moebs M, Sterry W (2008). Exp Opin Emerging Drugs 13:345-361

Erosive and erythematosquamous alterations of the skin by taking ACE-inhibitors. Mestel DS, Haas N, Sterry W (2007). JDDG 2007, Diagnosis Quiz, Supplement

FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Streit S*, Mestel DS*, Schmidt M, Ullrich A, Berking C. Br J Cancer. 2006 Jun 19;94(12):1879-86.*Both authors are equally contributed to the manuscript

Expression of BRN2, osteopontin and nestin in melanoma and nevi as indicators for tumor progression. Maier T, Flammiger A, Mestel D, Besch R, Nägele U, Sturm RA, Berking C (2006). Mel Res 16: 54

Expression of BRN2, osteopontin and nestin in melanoma and nevi. New markers of tumor progression? Maier T, Mestel D, Besch R, Nägele U, Sturm RA, Berking C (2006). Exp. Dermatol 15: 241